← Research LibraryThe BriefFY2025 10-K · headline figures audited against SEC data
Ardent Health revenue rose 6.0% to $6.3B, but net income fell 35.4% as net margin narrowed.
The read at a glance✓ Audited against SEC data
- Business mix — Acute care hospitals and sites of careNote
- Revenue — Revenue rose 6.0% to $6.3BOK
- Profitability — Net income fell 35.4%Watch
- Cash — Cash from ops rose 49.4%OK
- Balance sheet — Debt flat; equity up 13.8%OK
- Insiders — 0 buys / 0 sellsNote
- Accounting — Beneish no flag; other scores unavailableNote
Business
Ardent Health is a U.S. healthcare-services company with acute care hospitals, sites of care, and affiliated providers across six states.
Where the revenue comes from
Fiscal 2025, as Ardent Health, Inc. reports it. History and quarterly detail are in the app.
- Other managed care$2.8B
- Medicare$2.4B
- Medicaid$604.8M
- Self-pay and other$360.1M
Leadership changes
From Ardent Health, Inc.'s own filings, the day they're filed.
- Ethan Chernin · President · departureeff. 2026-03-24
- David Schultz · President · departureeff. 2025-06-16
- Robert A. DeMichiei · president and chief · appointmenteff. 2025-04-02
Latest filings
- 10-Q · Quarterly report2026-08-10
- 8-K · Company announcement2026-08-04
- 8-K · Company announcement2026-06-30
- 8-K · Company announcement2026-06-02
- 8-K · Company announcement2026-05-26
In the full recordFree for 14 days
- What changed🔒
- Insider signal🔒
- Growth quality🔒
- Margins & accounting🔒
- Capital allocation🔒
- Real risks🔒
- The long arc🔒
- Company history🔒
- Main tension🔒
- The filings, readable — with what changed vs the prior year highlighted🔒
- Full financial statements, industry-aware, sources cited throughout🔒
- Forensic score history & components — the trend, not one year🔒
- Ownership: insider buys/sells, clusters, activist stakes🔒
- Ana — ask about Ardent Health, Inc., every answer cited to the official filings🔒
Every figure comes from the company's filings, and analysis whose figures don't match SEC data is rejected before publication.
14-day free trial, no credit card. For research purposes only; not investment advice.